Esperion Therapeutics Expects FY24 Operating Expenses Of $225M-$245M, Including $20M In Non-cash Expenses Related To Stock Compensation
Portfolio Pulse from Benzinga Newsdesk
Esperion Therapeutics forecasts its FY24 operating expenses to be between $225M-$245M, which includes $20M in non-cash expenses due to stock compensation.
February 27, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Esperion Therapeutics anticipates FY24 operating expenses of $225M-$245M, including $20M in non-cash stock compensation expenses.
The projected increase in operating expenses, particularly the significant portion allocated to non-cash stock compensation, could signal to investors concerns about cash flow and profitability in the short term. This might lead to negative sentiment among investors, potentially impacting the stock price negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100